MBX Biosciences, Inc.’s Post

Peptides: The Power of Precision in Protein Building Blocks 🧬 Unlike their larger counterparts, proteins, peptides are smaller, more absorbable, and incredibly influential in our body's signaling and healing mechanisms. Use your RJV with our partner Peptide Bioregulator AND enter code "rejuv2024" to get a discount at checkout! Dive into the world of peptides with us and discover their therapeutic potential in modern medicine. #Biotech #Peptides #Therapeutics"

Peptide drug discovery is a fascinating field - learn more in our series of posts on this topic > #healthcareinnovation #Peptides #DrugDiscovery

#𝐏𝐞𝐩𝐭𝐢𝐝𝐞𝐬 𝐚𝐧𝐝 #𝐃𝐫𝐮𝐠𝐃𝐢𝐬𝐜𝐨𝐯𝐞𝐫𝐲 – 𝐏𝐚𝐫𝐭 1 Peptide drug discovery is a fascinating field. Did you know that the first peptide drug was insulin, isolated and purified from bovine pancreases to treat diabetes nearly a hundred years ago!? Though this process constituted a massive scientific and medical breakthrough, it was costly, inefficient, and limited to peptide hormones found naturally in the body. This led researchers to seek a better way to provide patients with much needed peptides. So what happened next? Tune in for our next post! #healthcareinnovation

Milk exosomes (mExos) have been demonstrated as oral delivery vehicles for protein and peptide drugs due to their superior ability to cross the epithelial barrier. However, certain challenges remain due to their intrinsic characteristics, including suboptimal drug loading efficiency, insufficient mucus penetration, and susceptibility to membrane protein loss. Here, researchers introduce a hybrid vesicle (mExos@DSPE-Hyd-PMPC) with adaptive surface properties, designed by fusing functionalized liposomes with native mExos, aiming to overcome the limitations associated with mExos and unleash their full potential in oral peptide delivery. https://lnkd.in/gwdzfGrG 

📢 Attention researchers! Invitrogen™ Vivofectamine™ Delivery Solutions have arrived to revolutionize in vivo delivery of nucleic acids with lipid nanoparticles (LNPs)! With their outstanding versatility and safety profile, Vivofectamine products are the ideal choice for both basic researchers and therapeutic development. But that's not all – we also offer custom products and services for supporting therapeutic development. From start to finish, our Vivofectamine Delivery Solutions can provide the delivery system you need for success. Don't miss out on the opportunity to enhance your research, accelerate your project timelines and take it to the next level. Check out Vivofectamine now and unlock new possibilities! 🔗 https://lnkd.in/e3cd5Mrk #delivery #lipidnanoparticles #nucleicacidmedicine #mrnavaccine #mrnatherapeutics #vivofectamine #LNP

Have you faced challenges with using traditional PEGs for bioconjugation? We have you covered. Uniform, single molecular weight, highly pure dPEG(R) is what you have been waiting for. The dPEGs or uniform PEGs from Vector Laboratories can be used to further optimize the PC and adsorption, distribution, metabolism, elimination, and toxicity (ADMET) properties of a therapeutic to achieve targeting, solubility, and stability requirements. Learn more here: https://bit.ly/4cEjKTA #VectorLaboratories #Bioconjugation #BioDesign #Biopharma

Pre-clinical data supporting the potential of INZ-701, Inozyme Pharma's lead ENPP1 enzyme replacement therapy (ERT) development candidate, to treat a broad range of diseases mediated by the PPi-Adenosine Pathway, was recently published in the journal Cells. The PPi-Adenosine Pathway is critical for regulating bone health and blood vessel function. The ENPP1 enzyme is a vital component of this pathway and plays an essential role in generating inorganic pyrophosphate (PPi), a key regulator of mineralization, and adenosine, a key regulator of intimal proliferation. INZ-701 is designed to increase PPi and adenosine, addressing deficiencies in these molecules and offering the potential to treat multiple rare diseases driven by disruptions in the PPi-Adenosine Pathway. Read the data: https://lnkd.in/eJ2HjEia #biotech

The drug candidate named MZ-101 recently highlighted by Drug Hunter, is an oral and selective small molecule GYS1 inhibitor that decreased accumulation of glycogen in skeletal muscle in a mouse model of Pompe disease. We have created a set of analogs for this molecule! https://buff.ly/3uVBecZ The development of MZ-101 is a significant breakthrough in inhibiting glycogen synthase 1 (GYS1). It selectively targets GYS1, reducing muscle glycogen without affecting GYS2 for liver glycogen. In mouse models of Pompe disease, MZ-101 treatment reduced glycogen accumulation in skeletal muscle as effectively as traditional enzyme replacement therapy (ERT). These results may indicate its potential for the treatment of Pompe disease and other glycogen storage disorders. Discover a wide array of in-stock and customizable molecules tailored to your needs at https://buff.ly/3Tprq4r ! #chemspace #openscience #research #science #drugdiscovery #chemicals #medicinalchemistry #drugdevelopment #chemistry #researchanddevelopment #search #chemicalindustry #science #structures

Predicting the pharmacokinetic and toxicological properties of a drug early can reduce the likelihood of failure, and subsequently the total cost of development. In this webinar, senior principal scientist at Visikol Inc. illustrates how combing their HUREL Micro Liver Models with the Agilent xCELLigence Real-Time Cell Analyzer identification of optimal treatment times, in addition to the evaluation of cytotoxicity onset and kinetics. Watch now: https://bit.ly/4aws9Gq

#Plasma_Therapy Market is estimated to grow at a high CAGR >> https://lnkd.in/d5vaF2Rw #Plasma therapy represents a #fundamental aspect of the #healing process; it plays an active role in the #immunological aspect of healing. It is considered an #innovation and promising approach extended to many #fields of #medicine, ranging from #bone #fracture, spinal fusion to the #treatment of several #traumatic or #degenerative pathologies and #ligaments. Octapharma, BioLife Plasma Services, Bio Products Laboratory Limited Kedrion Biopharma CSL #plasmatherapy #healingprocess #innovation #medicine #treatment #healthcareindustry #medicalscience